Cell Genesys received Fast Track designation from the U.

Cell Genesys received Fast Track designation from the U.S. Food and Drug Administration for GVAX immunotherapy for prostate cancer and Special Protocol Assessment for VITAL-1 and VITAL-2, the second ongoing Phase 3 trial is currently at around 90 locations in the U.S., Canada and Europe. VITAL-2 is enrolling metastatic HRPC patients who with with cancer-related pain. This study will compare GVAX cancer immunotherapy plus Taxotere chemotherapy Taxotere in combination with prednisone. The primary endpoint of the study is to improve the expected survival rate the company approximately 600 approximately 600 patients into VITAL-2 and plans to update the schedule for the completion of the recruitment by the end of 2007.

We visualized on researching methods of calculation, the clean up, and look for interesting patterns in thousands of mass spectrometry tissue images that you not necessarily be able to find or have time to focus to find with the naked eye, explained May Dongmei Wang, an assistant professor in the Wallace H. Coulter Department of Biomedical Engineering and Georgia Cancer Coalition Distinguished Cancer Scholar.The FDA suggests placing that these drugs to be disposed which by flushing down the sink or toilets. The goal is to Keep away away from children and others by them could be injured mistake.

Other entries from category "pregnancy":

Random entries